TNP-470: an angiogenesis inhibitor in clinical development for cancer

Bibliography

• ORCHARD PJ, SMITH CM, WOODS WG, DAY DL, DENHER LP, SHARPIO R: Treatment of haemangioendothe-liomas with alpha interferon. Lancet (1981) 2:565.
   PubMedGoogle Scholar
• EZEKOWITZ RAB, MULLIKEN JB, FOLKMAN J: Interferon a2 therapy for life-threatening hemangiomas in infancy. N Engl. J. Med. (1992)326:1456.
   PubMed Web of Science ®Google Scholar
• INGBER, DE: Discovery of TNP-470 and other angiogenesis inhibitors. In: Cancer Therapeutics: Experi-mental and Clinical Agents. B Teicher (Ed.) Humana Press, Totowa, NJ, USA (1996):283–298.
   Google Scholar
• INGBER D, FUJITA T, KISHIMOTO S et al.: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 348:555–557.
   PubMed Web of Science ®Google Scholar
• ••Original paper describing the screening and anti-angiogenicactivity of fumagillin derivatives, including TNP-470.
   Google Scholar
• INGBER DE, MADRI JA, FOLKMAN J: A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane disolution. Endocrinology (1986) 119:1768–1775.
   PubMed Web of Science ®Google Scholar
• INGBER DE: Fibronectin controls capillary endothelialcell growth by modulating cell shape. Proc. Natl. Acad. Sci. USA (1990) 87:3579–3583.
   PubMed Web of Science ®Google Scholar
• INGBER DE, MADRI JA, FOLKMAN J: Endothelial growth factors and extracellular matrix regulate DNA synthesis through modulation of cell and nuclear expansion in vitro. Cell Dev. Biol. (1987) 23:387–394.
   PubMed Web of Science ®Google Scholar
• KILLOUGH J, MAGILL G, SMITH R: The treatment of amebiasis with fumagillin. Science (1952) 115:71–72.
   PubMed Web of Science ®Google Scholar
• MCCOWEN M, CALLENDER M, LAWALISS JR, J: Fumagillin (H-3), a new antibiotic with amebicidal properties. Science (1951) 113:202–203.
   PubMed Web of Science ®Google Scholar
• HANSON F, EBLE T: An antiphage agent isolated fromAspergillus sp. J. Bacteriol. (1949) 58:527–529.
   PubMed Web of Science ®Google Scholar
• KUSAKA M, SUDO K, FUJITA T et al.: Potent antiangio-genic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun. (1991) 174:1070–1076.
   PubMed Web of Science ®Google Scholar
• KUSAKA M, SUDO KM, MATSUTANI E et al.: Cytostaticinhibition of endothelial cell growth by the angiogene-sis inhibitor TNP-470 (AGM-1470). Br. J. Cancer (1994) 69:212–216.
   PubMed Web of Science ®Google Scholar
• •Describes the effects of TNP-470 on endothelial cell cycle mediators.
   Google Scholar
• ANTOINE N, GREIMERS R, DE ROANNE C et al.: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res. (1994) 54:2073–2076.
   Google Scholar
• •See reference 12 for annotation.
   Google Scholar
• TOI M, SEKI M, UMEZAWA K, RHIM J: Resistance toTNP-470 in immortalized human umbilical vein endothelial cells transformed by human papilloma virus E6 and E7. (Abstr 306). Proc. Am. Assoc. Cancer Res. (1998) 39:45.
   Google Scholar
• ABE J, ZHOU W, TAKUWA N et al.: A fumagillin deriva-tive angiogenesis, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation of protooncogene expression in vascular endothelial cells. Cancer Res. (1994) 54:3407–3412.
   PubMed Web of Science ®Google Scholar
• •See reference 12 for annotation.
   Google Scholar
• TUDAN C, PELECH S, ATTARDO G: Inhibition of G1 phase-associated protein kinase C activity by AGM-1470. Ann. Oncol. (1998) 9:(Abstract 299).
   Google Scholar
• •See reference 12 for annotation.
   Google Scholar
• BUDSON AE, KO L, BRASEL C, BISCHOFF J: The angiogenesis inhibitor AGM-1470 selectively increases E-selectin. BBRC (1996) 225:141–145.
   PubMed Web of Science ®Google Scholar
• HORI A, IKEYAMA S, SUDO K: Suppression of cyclinDimRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem. Biophys. Res. Commun. (1994) 204:1067–1073.
   PubMed Web of Science ®Google Scholar
• SIN N, MENG L, WANG MQ, WEN JJ, BORNMANN WG, CREWS CM: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA (1997) 12:6099–6103.
   Google Scholar
• ••Describes the molecular target and mechanism of action ofTNP-470.
   Google Scholar
• BRADSHAW RA, BRICKEY WW, WALKER KW: N-terminalprocessing: the methionine aminopeptidase and N alpha-acetyl transferase families. Trends Biochem. Sci. (1998) 23:263–267.
   PubMed Web of Science ®Google Scholar
• TURK BE, GRIFFITH EC,WOLF S, BIEMANN K, CHANG YH, LIU JO: Selective inhibition of amino-terminal methio-nine processing by TNP-470 and ovalicin in endothe-lial cells. Chem. Biol. (1999) 6:823–833.
   PubMed Web of Science ®Google Scholar
• ••See reference 19 for annotation.
   Google Scholar
• YOSHIDA T, KANEKO Y, TSUKAMOTO A, HAN K, ICHINOSE M, KIMURA S: Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res. (1998) 58(16):3751–3756.
   PubMed Web of Science ®Google Scholar
• KLAUBER N, ROHAN RM, FLYNN E, D'AMATO RJ: Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nature Med. (1997) 3:443–446.
   PubMed Web of Science ®Google Scholar
• ••Discusses potential toxicity of TNP-470 on normalangiogenesis in the female reproductive system.
   Google Scholar
• FRASER H, DICKSON S, LUNN S: The effect of antiangio- genic agent TNP-470 on luteal establishment and function in the macaque and marmoset. IBC Angiogene-sis Conference (1998) (Abstract).
   Google Scholar
• KLEIN SA, BOND SJ, GUPTA SC, YACOUB OA, ANDERSON GL: Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J. Surg. Res. (1999) 82(2):268–274.
   PubMed Web of Science ®Google Scholar
• ••Discusses potential toxicity of TNP-470 on normalangiogenesis in wound healing.
   Google Scholar
• CHIANG SC, CHENG CH, MOULTON KS, KASZNICA JM, MOULTON SL: TNP-470 inhibits intraabdominal adhesion formation. Pediatr. Surg. (2000) 35(2):189–196.
   Web of Science ®Google Scholar
• TANAKA H, TANIGUCHI H, MUGITANI T et al.: Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing. Br. J. Surg. (1996) 83(10):1444–1447.
   PubMed Web of Science ®Google Scholar
• BREM H, EHRLICH P, TSAKAYANNIS DE, FOLKMAN J: Delay of wound healing by the angiogenesis inhibitor TNP-470. Surg. Forum (1997) 48:716–716.
   Google Scholar
• ••Suggests toxicity of TNP-470 on normal angiogenesis inwound healing may depend on treatment schedule.
   Google Scholar
• OLIVER SJ, BANQUERIGO ML, BRAHN E: Suppression of collagen-induced arthritis using and angiogenesis inhibitor, AGM-1470 and a microtubule stabilizer. Taxol Cell Immunol. (1994) 157:291–299.
   PubMed Web of Science ®Google Scholar
• OLIVER SJ, CHENG TP, BANQUERIGO ML, BRAHN E: Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol. (1 9 9 5) 166(2):196–206.
   Google Scholar
• MORI S, YOSHIKAWA H, HASHIMOTO J et al.: Antiangio-genic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2. Bone (1998) 22:99–105.
   PubMed Web of Science ®Google Scholar
• SASAKI A, ALCALDE RE, NISHIYAMA A et al.: Angiogene-sis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res. (1998) 58:462–467.
   PubMed Web of Science ®Google Scholar
• HARAGUCHI M, OKAMURA M, KONISHI et al.: Anti-angiogenic (TNP-470) inhibits mesangial cell proliferation in vitro and in Vivo. Kidney Int. (1997) 51:1838–1846.
   PubMed Web of Science ®Google Scholar
• ANTOINE N, DAUKANDT M, LOCIGNO R, HEINEN E, SIMAR 41, CASTRONOVO V: The potent angioinhibin AGM-1470 stimulates normal but not human tumoral lymphocytes. Tumour (1996) 82(1):27–30.
   PubMed Web of Science ®Google Scholar
• TSUJIMOTO H, HAGIWARA A, OSAKI K et al.: Therapeuticeffects of the angiogenesis inhibitor TNP-470 against carcinomatous peritonitis in mice. AntiCancer Drugs (1995) 6(3):438–442.
   PubMed Web of Science ®Google Scholar
• ANTOINE N, DAUKANDT M, HEINEN E, SIMAR CASTRONOVO V: In vitro and in vivo stimulation of the murine immune system by AGM-1470, a potent angiogenesis inhibitor. Am. J. Pathol. (1 99 6) 148:393–398.
   Google Scholar
• HORI K, LI HC, SAITO S, SATO Y: Increased growth andincidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470. Br. J. Cancer (1997) 75(12):1730–1734.
   PubMed Web of Science ®Google Scholar
• FUTAMI H, ISEKI H, EGAWA S, KOYAMA K, YAMAGUCHIK: Inhibition of lymphatic metastasis in a syngeneic rat fibrosarcoma model by an angiogenesis inhibitor, AGM-1470. Invasion Metastasis (1996) 16(2):73–82.
   PubMedGoogle Scholar
• OHTA Y, WATANABE Y, TABATA T et al.: Inhibition of lymph node metastasis by an anti-angiogenic agent, TNP-470. Br. J. Cancer (1997) 75(4):512–515.
   PubMed Web of Science ®Google Scholar
• DIDIER ES: Effects of albendazole, fumagillin and TNP-470 on microsporidial replication in vitro. Antimi-crob. Agents Chemother. (1997) 41:1541–1546.
   PubMed Web of Science ®Google Scholar
• COYLE C, KENT M, TANOWITZ HB, WITTNER M, WEISS LM: TNP-470 is an effective antirnicrosporial agent. J. Infect. Dis. (1998) 177:515–518.
   PubMed Web of Science ®Google Scholar
• TAP HOLDINGS, INC. Data on file (N-5-261). Deerfield, IL, USA. (1994).
   Google Scholar
• FIGG WD, YEH HJ, THIBAULT A et al.: Assay of the antiangiogenic compound TNP-470 and one of its metabolites, AGM-1883, by reversed phase high-performance liquid chromatography in plasma. J. Chromatogr. (1994) 652:187–194.
   PubMed Web of Science ®Google Scholar
• •Describes HPLC assay for TNP-470 in human plasma.
   Google Scholar
• PLACIDI L, SCOTT EC, DE SOUSAG, RAHMANI R, PLACIDI M, SOMMADOSSI JP: Interspecies variability of TNP-470 metabolism, using primary monkey, rat and dog cultured hepatocytes. Drug Metab. Disp. (1997) 25(1):94–99.
   PubMed Web of Science ®Google Scholar
• PLACIDI L, CRETTON S, DE SOUSAG, RAHMANI R, PLACIDI M, SOMMADOSSI JP: Disposition and metabo-lism of the angiogenic moderator 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res. (1995) 55(14):3036–3042.
   PubMed Web of Science ®Google Scholar
• CRETTON S, PLACIDI L, MCCLURE H, ANDERSON DC, SOMMADOSSI JP : Pharmacokinetics and metabolism of 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys. Cancer Chemother. Pharmacol. (1996) 38(2):117–122.
   PubMed Web of Science ®Google Scholar
• ONG VS, STAMM GE, MENACHERRY S CHU, S: Quantita-tion of TNP-470 and its metabolites in human plasma: sample handling, assay performance and stability. J. Chromatogr. B. Biomed. Sci. Appl. (1998) 710:173–182.
   PubMedGoogle Scholar
• •See reference 43 for annotation.
   Google Scholar
• FIGG WD, PLUDA JM, LUSH RM et al.: The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy (1997) 17(1):91–97.
   PubMed Web of Science ®Google Scholar
• •Describes pharmacokinetics of TNP-470 in humans.
   Google Scholar
• BHARGAVA P, MARSHALL J, RIZVI N et al.: A study of TNP-470 in patients with advanced cancer. Proc. Am. Assoc. Cancer Res. (1997) 38:221.
   Google Scholar
• ••Reports clinical findings of TNP-470 in cancer patients.
   Google Scholar
• YAMAOKA M, YAMAMOTO T, IKEYAMA S, SUDO K, FUJITA T: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. (1993) 53:5233–5236.
   PubMed Web of Science ®Google Scholar
• TAKAMIYA Y, BREM H, OJEIFO J, MINETA T, MARTUZARU: AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery (1994) 34:869–875.
   PubMed Web of Science ®Google Scholar
• IKEBE T, YAMAMOTO T, KUBO S et al.: Suppressive effect of the angiogenesis inhibitor TNP-470 on the development of carcinogenesis -induced hepatic nodules in rats. Jpn J. Cancer Res. (1998) 89:143–149.
   PubMedGoogle Scholar
• TANAKA Y, KAWAMATA H, FUJIMOTO K, OYASU R: Angiogenesis inhibitor TNP-470 suppresses tumorige-nesis in rat urinary bladder. J. Urol. (1997) 157:683–688.
   PubMed Web of Science ®Google Scholar
• PARANGI S, O'REILLY M, CHRISTOFORI G et al.: Anti-angiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA (1996) 93:2002–2007.
   PubMedGoogle Scholar
• HAMA Y, FUJIMORI M, USUDA N, NAKAGAWARA A, AMANO J: Therapeutic efficacy of the angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. Proc. Am. Assoc. Cancer Res. (1996) 37:397.
   Google Scholar
• SINGH Y, SHIKATA N, KIYOZUKA Y et al.: Inhibition oftumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cells lines in vitro and in vivo. Breast Cancer Res. Treat. (1997) 45:15–27.
   PubMed Web of Science ®Google Scholar
• MCLESKY SW, ZHANG L, KHARBANDA S et al.: Fibroblastgrowth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res. Treat. (1996) 39:103–117.
   PubMed Web of Science ®Google Scholar
• YANASE T, TAMURA M, FUJITA K, KODAMA S, TANAKA K:Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. (1993) 53:2566–2570.
   PubMed Web of Science ®Google Scholar
• TANAKA T, KONNO H, MATSUDA I, NAKAMURA S, BABAS: Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-1470. Cancer Res. (1995) 55:836–839.
   PubMed Web of Science ®Google Scholar
• KONNO H, TANAKA T, MATSUDA I et al.: Comparison ofthe inhibitory effect of the angiogenesis inhibitor TNP-1470 and mitomycin c on the growth and liver metastasis of human colon cancer. Int. J. Cancer (1995) 61:268–271.
   PubMed Web of Science ®Google Scholar
• YANO T, TANASE M, WATANABE A et al.: Enhancementeffect of an anti- angiogenic agent, TNP- 470, on hyperthermia-induced growth suppression of human esophageal and gastric cancers transplanTable to nude mice. Anti Cancer Res (1995) 15(4):1355–1358.
   PubMed Web of Science ®Google Scholar
• KANAI T, KONNO H, TANAKA T et al.: Effect of angiogenesis inhibitor TNP-470 on the progression of gastric cancer xenotransplanted into nude mice. Int J Cancer (1997) 71:838–841.
   PubMed Web of Science ®Google Scholar
• SHISHIDO T, YASOSHIMA T, DENNO R, SATO N, HIRATAK: Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP-470. Jpn J. Cancer Res. (1996) 87:958–962.
   PubMedGoogle Scholar
• BERNSEN HJ, RIJKEN PF, PETERS H, BAKKER H, VAN DERKOGEL AJ: The effect of anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J. NeuroOncol. (1998) 38:51–57.
   PubMed Web of Science ®Google Scholar
• TAKAMIYA Y, BREM H, OJEIFO J, MINETA T, MARTUZARL: AGM-1470 inhibits the growth of human glioblas-toma cells in vitro and in vivo. Neurosurgery (1994) 34:869–875.
   PubMed Web of Science ®Google Scholar
• GLEICH LL, ZIMMERMAN N, WANG YO, GLUCKMAN JL:Angiogenic inhibition for the treatment of head and neck cancer. AntiCancer Res. (1998) 18:2607–2609.
   PubMed Web of Science ®Google Scholar
• XIA JL, YANG BH, TANG ZY, SUN FX, XUE Q, GAO DM:Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. (1997) 123:383–387.
   PubMed Web of Science ®Google Scholar
• ISOBE N, UOZUMI T, KURISU K, KAWAMOTO K: Experi-mental studies of the antitumor effect of TNP-470 on malignant brain tumors. Antitumor effect of TNP-470 on a human medulloblastoma xenograft line. Neurope-diatrics (1996) 27:136–142.
   Google Scholar
• TAKI T, OHNISHI T, ARITA N et al.: Anti-proliferativeeffects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis.J. NeuroOncol. (1994) 19:251–248.
   Google Scholar
• WASSBERG E, PAHLMAN S, WESTLIN JE, CHRISTOF-FERSON R: The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr. Res. (1997) 41:327–333.
   PubMed Web of Science ®Google Scholar
• TAKAMIYA Y, FRIEDLANDER RM, BREM H, MALICK A, MARTUZA RL: Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470.J. Neurosur-gery (1993) 78:470–476.
   PubMed Web of Science ®Google Scholar
• KATO T, SATO K, KAKINUMA H, MATSUDA Y: Enhanced suppression of tumor growth by combination of angiogenesis inhibitor o-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res. (1994) 54:5143–5147.
   PubMed Web of Science ®Google Scholar
• BHARGAVA P, DORDAL MS, HAWKINS MJ: TNP-470. In:Angiogenesis in Health, and Disease, Basic Mechanisms and Clinical Applications. G Rubayani (Ed.) Marcel Dekker, Inc., New York, USA 387–406.
   Google Scholar
• CASTRONOVO V, BELOTTI D: TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur. J. Cancer (1996) 32A:2520–2527.
   PubMed Web of Science ®Google Scholar
• YANAI S, OKADA H, MISAKI M et al.: Antitumor activity of a medium-chain triglyceride solution of the angiogenesis inhibitor TNP-470 (AGM1470) when administered via the hepatic artery to rats bearing Walker 256 carcinosarcoma in the liver. J. Pharmacol. Exp. Ther. (1994) 271:1267–1273.
   PubMed Web of Science ®Google Scholar
• YANAI S, OKADA H, SAITO K et al.: Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing vx-2 carcinoma. Pharmacol. Res. (1997) 12:653–657.
   Google Scholar
• TEICHER BA, SOTOMAYOR EA, HUANG ZD: Antiangio-genic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. (1992) 52:6702–6704.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, HOLDEN SA, ARA G et al.: Potentiation ofcytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer (1994) 57:920–925.
   PubMed Web of Science ®Google Scholar
• VOEST EE, KENYON BM, O'REILLY MS, TRUITT G, D'AMATO RJ, FOLKMAN J: Inhibition of angiogenesis in vivo by interleukin 12 (see comments). J. Natl. Cancer Inst. (1995) 87:581–586.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, HOLDEN SA, ARA G, KORBUT T, MENON K:Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother. Pharmacol. (1996) 38:169–177.
   PubMed Web of Science ®Google Scholar
• HERBST RS, TAKEUCHI H, TEICHER BA: Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small cell lung and breast cancer carcinoma models. Cancer Chemother. Pharmacol. (1998) 41:497–504.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, HOLDEN SA, DUPUIS NP etai.: Potentiationof cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res. Treat. (1995) 36:227–236.
   Google Scholar
• SATOH H, ISHIKAWA H, FUJIMOTO M et al.: Combinedeffects of TNP-470 and Taxol in human non-small cell lung cancer cell lines. AntiCancer Res. (1998) 18:1027–1030.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO J, HORI M, ICHIGO S, HIROSE R, SAKAGUCHI H, TAMAYA T: Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and o-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Lett. (1997) 113:187–194.
   PubMed Web of Science ®Google Scholar
• DEVINENI D, KLEIN-SZANTO A, GALLO JM: Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res. (1996) 56:1983–1987.
   PubMed Web of Science ®Google Scholar
• MURATA R, NISHIMURA Y, HIRAOKA M: An antiangio-genic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. J. Radiat Oncol. Biol. Phys. (1997) 37:1107–1113.
   PubMed Web of Science ®Google Scholar
• NISHIMURA Y, MURATA R, HIRAOKA M: Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. Br. J. Cancer (1996) 73(3):270–274.
   PubMed Web of Science ®Google Scholar
• MATSUOKA S: Anti-tumor effects of an angiogenesisinhibitor, TNP-470 (AGM-1470) alone and in combina-tion with cisplatinum and changes in serum copper levels in liver cancer bearing rats. Hokkaido. Igaku Zasshi (1996) 71:69–80.
   PubMedGoogle Scholar
• SATOH H, ISHIKAWA H, FUJIMOTO H et al.: Angiocyto-toxic therapy in human non-small cell lung cancer cell lines - advantage of combined effects of TNP-470 and SN-38. Acta Oncol. (1998) 37:85–90.
   PubMed Web of Science ®Google Scholar
• TAKECHI A Effect of angiogenesis inhibitor TNP-470 on vascular formation in pituitary tumors induced by estrogen in rats. Neurol. Med. Chir. (Tokyo) (1994) 34:729–733.
   PubMedGoogle Scholar
• TAKECHI A, UOZUMI T, KAWAMOTO K, ITO A, KURISHU K, SUDO K: Inhibitory effect of TNP-470, a new anti-angiogenic agent, on the estrogen induced rat pituitary tumors. AntiCancer Res. (1994) 14:157–162.
   PubMed Web of Science ®Google Scholar
• MAIER JA, DELTA D, THORPE PE, GASPARINI G: In vitro inhibition of endothelial cell growth by the antiangio-genic drug AGM-1470 (TNP-470) and the anti-endog,lin antibody TEC-11. AntiCancer Drugs (1997) 8(3):238–244.
   PubMed Web of Science ®Google Scholar
• KANO Y, YAMAZAKI R, SHIRAI Y, KAKUTA H: Effect of injection of anti-bEGF antibody (3H3) and angiogene-sis inhibitor (TN P-470) on mouse syngeneic solid tumor (NR-S1). Biotherapy (1996) 10(3):530–532.
   Google Scholar
• DEZUBE BJ, VON ROENN JH, HOLDEN-WILTSE J: et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a Phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. Clin Oncol. (1998) 16(4):1444.
   Google Scholar
• ••Reports clinical findings of TNP-470 in cancer patients.
   Google Scholar
• BHARGAVA P, MARSHALL JL, RIZVI N et al.: A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. (1999) 5(8):1989–95.
   PubMed Web of Science ®Google Scholar
• ••See reference 94 for annotation.
   Google Scholar
• KUDELKA AP, LEVY T, VERSCHRAEGEN CF et al.: A Phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res. (1997) 3(9):1501–5.
   PubMed Web of Science ®Google Scholar
• ••See reference 94 for annotation.
   Google Scholar
• KUDELKA AP, VERSCHRAEGEN CF, LOYER E: Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N. Engl. J. Med. (1998) 338(14):991–992.
   PubMed Web of Science ®Google Scholar
• ••Reports case study of complete response using TNP-470 incervical cancer.
   Google Scholar
• STADLER WM, KUZEL T, SHAPIRO C, SOSMAN J, CLARK J, VOGELZANG NJ: Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. (1999) 17(8):2541–2545.
   PubMed Web of Science ®Google Scholar
• ••See reference 94 for annotation.
   Google Scholar
• ZUKIWSKI A, GUTTERMAN J, BUT C et al.: Phase I trial of angiogenesis inhibitor TNP-470 (AGM-1470) in patients with androgen-independent prostate cancer. Proc. Am. Soc. Clin. Oncol. (1994) 13:A7495.
   Google Scholar
• ••See reference 94 for annotation.
   Google Scholar
• HORTI J, DIXON SC, LOGOTHETIS CJ, GUO Y, REED E, FIGG WD: Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br. J. Cancer (1999) 79(9–10):1588-1593 • Discusses effects of TNP-470 on the tumour surrogate marker PSA.
   Google Scholar